• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sanara MedTech's Earnings: A Preview

    3/22/24 10:00:41 AM ET
    $SMTI
    Industrial Specialties
    Health Care
    Get the next $SMTI alert in real time by email

    Sanara MedTech (NASDAQ:SMTI) is set to give its latest quarterly earnings report on Monday, 2024-03-25. Here's what investors need to know before the announcement.

    Analysts estimate that Sanara MedTech will report an earnings per share (EPS) of $-0.13.

    Sanara MedTech bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

    New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

    Historical Earnings Performance

    Last quarter the company missed EPS by $0.13, which was followed by a 19.36% increase in the share price the next day.

    Here's a look at Sanara MedTech's past performance and the resulting price change:

    Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
    EPS Estimate 0 -0.13 -0.33 -0.26
    EPS Actual -0.13 -0.22 -0.14 -0.51
    Price Change % 19.0% -10.0% -8.0% 1.0%

    eps graph

    Stock Performance

    Shares of Sanara MedTech were trading at $37.72 as of March 21. Over the last 52-week period, shares are down 1.75%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

    To track all earnings releases for Sanara MedTech visit their earnings calendar on our site.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $SMTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SMTI

    DatePrice TargetRatingAnalyst
    3/26/2025$50.00 → $51.00Buy
    H.C. Wainwright
    12/23/2024$50.00Buy
    H.C. Wainwright
    5/20/2022$45.00 → $40.00Overweight
    Cantor Fitzgerald
    6/30/2021$45.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SMTI
    SEC Filings

    View All

    Sanara MedTech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sanara MedTech Inc. (0000714256) (Filer)

    1/23/26 7:45:35 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Sanara MedTech Inc. (0000714256) (Filer)

    11/26/25 4:10:47 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Sanara MedTech Inc.

    10-Q - Sanara MedTech Inc. (0000714256) (Filer)

    11/12/25 4:03:11 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance

    FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year ending December 31, 2026. Selected Fourth Quarter and Full Year 2025 Preliminary Financial Results (Unaudited): Net revenue for the fourth quarter of 2025 is expected to be in th

    1/23/26 7:30:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Receives Innovative Technology Contract from Vizient for BIASURGE® Advanced Surgical Solution

    Contract awarded for products that bring improvement to the healthcare industry FORT WORTH, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara MedTech," "Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today announced that its BIASURGE® Advanced Surgical Solution ("BIASURGE") product has received an Innovative Technology contract from Vizient® Inc. ("Vizient"), the nation's largest provider-driven healthcare performance improvement company. The contract was awarded based on the

    1/7/26 4:05:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. and Biomimetic Innovations Provide Update on OsStic™

    Poised for U.S. market launch in Q1 2027 following the achievement of recent milestones and OsStic's granted patent in 2025 FORT WORTH, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, together with Biomimetic Innovations Ltd ("BMI"), today provided an update on progress related to their strategic alliance. In addition, Sanara reaffirmed its plans to introduce OsStic™ Synthetic Injectable Structural Bio-Adhesive ("OsStic") to the U.S.

    12/10/25 8:37:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Yon Seth D was granted 28,563 shares, increasing direct ownership by 47% to 89,851 units (SEC Form 4)

    4 - Sanara MedTech Inc. (0000714256) (Issuer)

    9/16/25 4:05:33 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    New insider Mackey Ashley M claimed ownership of 2,412 shares (SEC Form 3)

    3 - Sanara MedTech Inc. (0000714256) (Issuer)

    9/4/25 4:10:06 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Ch. Acct. & Ch. Admin. Officer Mcneil Michael D. covered exercise/tax liability with 2,324 shares, decreasing direct ownership by 8% to 28,587 units (SEC Form 4)

    4 - Sanara MedTech Inc. (0000714256) (Issuer)

    8/19/25 5:17:20 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Sanara MedTech with a new price target

    H.C. Wainwright reiterated coverage of Sanara MedTech with a rating of Buy and set a new price target of $51.00 from $50.00 previously

    3/26/25 7:42:25 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Smtek with a new price target

    H.C. Wainwright initiated coverage of Smtek with a rating of Buy and set a new price target of $50.00

    12/23/24 7:26:26 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Cantor Fitzgerald resumed coverage on Smtek with a new price target

    Cantor Fitzgerald resumed coverage of Smtek with a rating of Overweight and set a new price target of $40.00 from $45.00 previously

    5/20/22 9:07:28 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Leadership Updates

    Live Leadership Updates

    View All

    Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments

    Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer FORT WORTH, TX, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the expansion of the Company's executive leadership team with new appointments. Elizabeth Taylor has been appointed to the position of Chief Financia

    1/21/25 4:08:00 PM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer

    FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer. Zach Fleming, Sanara's Chief Executive Officer, stated, "Jake and Tyler are seasoned executives with a wealth of experience in the medical device and woun

    4/5/24 9:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Announces the Appointment of Zachary B. Fleming as Chief Executive Officer

    FORT WORTH, TX, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zachary ("Zach") B. Fleming has been appointed Chief Executive Officer effective January 1, 2022. Ron Nixon, Sanara's Executive Chairman, stated, "Zach is an outstanding leader who has been a driving force behind the development and execution of our surgical wound strategy. During his time as President of the Surgical Division, he has overseen double-digit year over year revenue growth of our business and steered the division through the ch

    12/28/21 9:15:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Financials

    Live finance-specific insights

    View All

    Sanara MedTech Inc. Reports Third Quarter 2025 Financial Results (Unaudited)

    Net Revenue Increased 22% Year-Over-Year in Q3; Increased 25% Year-Over-Year in First Nine Months of 2025 FORT WORTH, TX, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary (2)  ●Net revenue increased 22% to $26.3 million, compared to $21.7 million in the third quarter of 2024. ●Net income from continuing operations of $

    11/12/25 7:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech to Report Third Quarter 2025 Financial Results on November 12, 2025

    FORT WORTH, TX, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced it will report its third quarter 2025 financial results on Wednesday, November 12, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on November 12, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended September 30, 2025 and hold a question and answer session at the end of the call. Th

    10/1/25 7:30:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)

    Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today reported its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary  ●Net revenue increased 28% to

    8/13/25 7:00:00 AM ET
    $SMTI
    Industrial Specialties
    Health Care

    $SMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Sanara MedTech Inc.

    SC 13G - Sanara MedTech Inc. (0000714256) (Subject)

    10/8/24 5:36:55 PM ET
    $SMTI
    Industrial Specialties
    Health Care